GAD1 and Parkinson disease: In a phase I clinical trial, Kaplitt et al., investigated an AAV-mediated gene therapy approach for advanced PD patients, where serotype 2 was used as a vector for unilateral subthalamic delivery of the glutamic acid decarboxylase (GAD) gene [229].